DK0934069T3 - Fremgangsmåde og apparat til behandling af lipid- og glucosemetabolismelidelser - Google Patents

Fremgangsmåde og apparat til behandling af lipid- og glucosemetabolismelidelser

Info

Publication number
DK0934069T3
DK0934069T3 DK97923573T DK97923573T DK0934069T3 DK 0934069 T3 DK0934069 T3 DK 0934069T3 DK 97923573 T DK97923573 T DK 97923573T DK 97923573 T DK97923573 T DK 97923573T DK 0934069 T3 DK0934069 T3 DK 0934069T3
Authority
DK
Denmark
Prior art keywords
agonist
glucose metabolism
adrenergic
dopamine
metabolism disorders
Prior art date
Application number
DK97923573T
Other languages
English (en)
Inventor
Anthony H Cincotta
Original Assignee
Pliva Istrazivanje I Razvoj D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Istrazivanje I Razvoj D filed Critical Pliva Istrazivanje I Razvoj D
Application granted granted Critical
Publication of DK0934069T3 publication Critical patent/DK0934069T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
DK97923573T 1996-05-07 1997-05-06 Fremgangsmåde og apparat til behandling af lipid- og glucosemetabolismelidelser DK0934069T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1737796P 1996-05-07 1996-05-07
US1933696P 1996-06-06 1996-06-06
PCT/US1997/007701 WO1997041873A1 (en) 1996-05-07 1997-05-06 Method and composition for the treatment of lipid and glucose metabolism disorders

Publications (1)

Publication Number Publication Date
DK0934069T3 true DK0934069T3 (da) 2007-03-19

Family

ID=26689794

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97923573T DK0934069T3 (da) 1996-05-07 1997-05-06 Fremgangsmåde og apparat til behandling af lipid- og glucosemetabolismelidelser

Country Status (9)

Country Link
EP (2) EP1776955B1 (da)
AT (1) ATE344668T1 (da)
CA (1) CA2254116C (da)
DE (1) DE69736928T2 (da)
DK (1) DK0934069T3 (da)
ES (2) ES2393303T3 (da)
HK (1) HK1108312A1 (da)
PT (1) PT934069E (da)
WO (1) WO1997041873A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6366298B1 (en) 1999-06-03 2002-04-02 Netzero, Inc. Monitoring of individual internet usage
US9655865B2 (en) * 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20180066272A (ko) 2006-11-09 2018-06-18 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
AU2013263800B2 (en) * 2007-03-30 2016-05-05 Veroscience Llc Methods of treating metabolic syndrome using dopamine receptor agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
WO2009062113A1 (en) 2007-11-07 2009-05-14 Burnham Institute For Medical Research Method and compounds for modulating insulin production
AU2015201255B2 (en) * 2008-01-14 2016-05-19 Veroscience, Llc Parenteral formulations of dopamine agonists
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
IL300868A (en) 2012-06-06 2023-04-01 Orexigen Therapeutics Inc Methods for treating overweight and obesity
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3419293A (en) * 1991-12-23 1993-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The A therapeutic process for the treatment of the pathologies of type II diabetes

Also Published As

Publication number Publication date
ES2393303T3 (es) 2012-12-20
EP0934069B1 (en) 2006-11-08
DE69736928T2 (de) 2007-06-28
WO1997041873A1 (en) 1997-11-13
EP1776955B1 (en) 2012-08-15
HK1108312A1 (en) 2008-05-02
EP1776955A1 (en) 2007-04-25
ES2277357T3 (es) 2007-07-01
CA2254116C (en) 2009-10-20
ATE344668T1 (de) 2006-11-15
PT934069E (pt) 2007-02-28
EP0934069A1 (en) 1999-08-11
CA2254116A1 (en) 1997-11-13
EP0934069A4 (en) 2002-12-04
DE69736928D1 (de) 2006-12-21

Similar Documents

Publication Publication Date Title
DK0934069T3 (da) Fremgangsmåde og apparat til behandling af lipid- og glucosemetabolismelidelser
DK0772451T3 (da) Behandling af type II-diabetes mellitus med amylin-agonister
DK0840601T3 (da) THIP til behandling af søvnforstyrrelser
LV11830A (lv) Metode un ierice notekudens attirisanai
DE69516866D1 (de) Stereochemische wortmanninderivate
DK0726765T3 (da) Apparat og fremgangsmåde til fremstilling af faste former med styret frigivelse af den aktive bestanddel
DK0789567T3 (da) En fremgangsmåde til behandling af vaskulære hovedpiner
DK0942751T3 (da) Præparater til behandling af perifere nuropatier indeholdende antidepressiver og/eller monoaminoxidase-inhibitorer og/eller vitamin B12 og/eller prekursere til eller inducere af en neurotransmitter
DE60025368D1 (de) Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DK0804196T3 (da) Anvendelse af serotoninantagonister (5HT 3) til behandling af fibromyalgia
EA200001129A3 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
DE69523324D1 (de) Behandlung von Angstzuständen
DK1124556T3 (da) Anvendelse af optisk rent (R)-tofisopam til behandling og forebyggelse af angstsygdomme
SE9501808D0 (sv) New process
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
DK0674521T3 (da) Fremgangsmåde til behandling af kronisk prostatitis med 17beta-N-tertbutylcarbamoyl-4-aza-5a-andost-1-en-3-on
DK1385993T3 (da) Fremgangsmåde til detektering og behandling af tuberøs sclerose kompleksrelaterede lidelser
GB9726199D0 (en) A method of and apparatus for detecting components of a mixture seperated by chromatography
EA200100182A1 (ru) Лечение состояний тревожности
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
Jordan Behavioural and neurochemical correlates of drugs acting at imidazoline and α2-adrenoceptor binding sites